1. Home
  2. COGT vs AIO Comparison

COGT vs AIO Comparison

Compare COGT & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COGT
    SELLHOLDBUYas of 2 days ago
  • AIO
    SELLHOLDBUYas of 2 days ago
  • Stock Information
  • Founded
  • COGT 2014
  • AIO 2019
  • Country
  • COGT United States
  • AIO United States
  • Employees
  • COGT N/A
  • AIO N/A
  • Industry
  • COGT Biotechnology: Pharmaceutical Preparations
  • AIO Finance/Investors Services
  • Sector
  • COGT Health Care
  • AIO Finance
  • Exchange
  • COGT Nasdaq
  • AIO Nasdaq
  • Market Cap
  • COGT 900.3M
  • AIO 760.3M
  • IPO Year
  • COGT 2018
  • AIO N/A
  • Fundamental
  • Price
  • COGT $7.84
  • AIO $23.79
  • Analyst Decision
  • COGT Buy
  • AIO
  • Analyst Count
  • COGT 6
  • AIO 0
  • Target Price
  • COGT $14.20
  • AIO N/A
  • AVG Volume (30 Days)
  • COGT 1.8M
  • AIO 141.5K
  • Earning Date
  • COGT 11-12-2024
  • AIO 01-01-0001
  • Dividend Yield
  • COGT N/A
  • AIO 9.05%
  • EPS Growth
  • COGT N/A
  • AIO N/A
  • EPS
  • COGT N/A
  • AIO N/A
  • Revenue
  • COGT N/A
  • AIO N/A
  • Revenue This Year
  • COGT N/A
  • AIO N/A
  • Revenue Next Year
  • COGT N/A
  • AIO N/A
  • P/E Ratio
  • COGT N/A
  • AIO N/A
  • Revenue Growth
  • COGT N/A
  • AIO N/A
  • 52 Week Low
  • COGT $4.28
  • AIO $15.09
  • 52 Week High
  • COGT $12.61
  • AIO $20.25
  • Technical
  • Relative Strength Index (RSI)
  • COGT 31.99
  • AIO 46.79
  • Support Level
  • COGT $7.30
  • AIO $24.15
  • Resistance Level
  • COGT $8.56
  • AIO $24.99
  • Average True Range (ATR)
  • COGT 0.67
  • AIO 0.55
  • MACD
  • COGT -0.08
  • AIO -0.20
  • Stochastic Oscillator
  • COGT 16.77
  • AIO 21.85

Stock Price Comparison Chart: COGT vs AIO

COGT
AIO
AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober024681012141618202224262830COGT VS AIO

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest

Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use